A Pilot Study of Pacritinib in Combination With Low Dose Decitabine in Patients With Intermediate-High Risk Myelofibrosis or MPN/MDS Syndromes
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 10 May 2017
At a glance
- Drugs Pacritinib (Primary) ; Decitabine
- Indications Chronic myeloid leukaemia; Myelodysplastic syndromes; Myelofibrosis
- Focus Adverse reactions
- 03 May 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 03 Mar 2017 Planned End Date changed from 1 Oct 2019 to 30 Jun 2020.
- 03 Mar 2017 Planned primary completion date changed from 1 Oct 2019 to 30 Jun 2020.